ArticleWorld journal of clinical cases2024
Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts.
Article in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 9 citations in OpenAlex.
- Integrative advances in biomarker-driven prostate cancer management from genomic discovery to precision oncology.Discover oncology · 2026Review
- Intermittent Fasting and Androgen Receptor Signaling in Prostate Cancer: Metabolic Crosstalk and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Evidence for Genotype-Specific Optimal Blood Lead Levels for Cancer Risk:International journal of molecular sciences · 2026Article
- Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5/6, and Ki-67 expression.Open life sciences · 2026Article
- Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer.The Prostate · 2025Article
- Construction and validation of a lysine beta hydroxybutyrylation related molecular model for predicting biochemical recurrence of prostate cancer.Scientific reports · 2025Article
- Value of integrated PET-IVIM MRI in predicting Ki-67 expression in newly diagnosed prostate cancer.Scientific reports · 2025Article
- Transcriptomic signatures of prostate cancer progression: a comprehensive RNA-seq study.3 Biotech · 2025Article
- Role of multi‑omics in advancing the understanding and treatment of prostate cancer (Review).Molecular medicine reports · 2025Review
- Correction to: Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts.World journal of clinical cases · 2024Article
- Immunoexpression of Cyclin D1, P53 and Ki67 in prostatic acinar adenocarcinomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is a widespread malignancy, predominantly affecting elderly males, and current methods for diagnosis and treatment of this disease continue to fall short. The marker Ki-67 (MKI67) has been previously demonstrated to correlate with the proliferation and metastasis of various cancer cells, including those of PCa. Hence, verifying the association between MKI67 and the diagnosis and prognosis of PCa, using bioinformatics databases and clinical data analysis, carries significant clinical implications.
aimTo explore the diagnostic and prognostic efficacy of antigens identified by MKI67 expression in PCa.
methodsFor cohort 1, the efficacy of MKI67 diagnosis was evaluated using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. For cohort 2, the diagnostic and prognostic power of MKI67 expression was further validated using data from 271 patients with clinical PCa.
resultsIn cohort 1, MKI67 expression was correlated with prostate-specific antigen (PSA), Gleason Score, T stage, and N stage. The receiver operating characteristic (ROC) curve showed a strong diagnostic ability, and the Kaplan-Meier method demonstrated that MKI67 expression was negatively associated with the progression-free interval (PFI). The time-ROC curve displayed a weak prognostic capability for MKI67 expression in PCa. In cohort 2, MKI67 expression was significantly related to the Gleason Score, T stage, and N stage; however, it was negatively associated with the PFI. The time-ROC curve revealed the stronger prognostic capability of MKI67 in patients with PCa. Multivariate COX regression analysis was performed to select risk factors, including PSA level, N stage, and MKI67 expression. A nomogram was established to predict the 3-year PFI.
conclusionMKI67 expression was positively associated with the Gleason Score, T stage, and N stage and showed a strong diagnostic and prognostic ability in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.